These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31455199)

  • 1. Approximate confidence limit for the reference scaled bioequivalence with a parallel design.
    Liao JJZ; Li Y
    J Biopharm Stat; 2020 Mar; 30(2):231-243. PubMed ID: 31455199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.
    Jiang W; Makhlouf F; Schuirmann DJ; Zhang X; Zheng N; Conner D; Yu LX; Lionberger R
    AAPS J; 2015 Jul; 17(4):891-901. PubMed ID: 25840883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
    Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
    AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence testing by statistical shape analysis.
    Pereira LM
    J Pharmacokinet Pharmacodyn; 2007 Aug; 34(4):451-84. PubMed ID: 17554610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
    Tothfalusi L; Endrenyi L
    AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence review for drug interchangeability.
    Chow SC; Shao J
    J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size determination for individual bioequivalence inference.
    Chiang C; Hsiao CF; Liu JP
    PLoS One; 2014; 9(10):e109746. PubMed ID: 25310592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical evaluation of the scaled criterion for drug interchangeability.
    Li J; Chow SC
    J Biopharm Stat; 2017; 27(2):282-292. PubMed ID: 27937059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling type I error in the reference-scaled bioequivalence evaluation of highly variable drugs.
    Ocaña J; Muñoz J
    Pharm Stat; 2019 Oct; 18(5):583-599. PubMed ID: 31190418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing bioequivalence and drug interchangeability.
    Chen M; Chow SC
    J Biopharm Stat; 2017; 27(2):272-281. PubMed ID: 27936343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons.
    Gwaza L; Gordon J; Potthast H; Welink J; Leufkens H; Stahl M; García-Arieta A
    Eur J Clin Pharmacol; 2015 Sep; 71(9):1083-9. PubMed ID: 26105964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the bioequivalence of highly-variable drugs and drug products.
    Tothfalusi L; Endrenyi L; Midha KK; Rawson MJ; Hubbard JW
    Pharm Res; 2001 Jun; 18(6):728-33. PubMed ID: 11474774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A parametric confidence interval for a moment-based scaled criterion for individual bioequivalence.
    Kimanani EK; Potvin D
    J Pharmacokinet Biopharm; 1997 Oct; 25(5):595-614. PubMed ID: 9679224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers.
    Bendas ER; Rezk MR; Badr KA
    Clin Drug Investig; 2018 May; 38(5):439-448. PubMed ID: 29417463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of in vitro-in vivo equivalence of highly variable drugs - a generic product development perspective.
    Pathak SM; Aggarwal D; Venkateswarlu V
    Pharm Dev Technol; 2014 Jun; 19(4):401-10. PubMed ID: 23607272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.
    Hammami MM; De Padua SJS; Hussein R; Al Gaai E; Khodr NA; Al-Swayeh R; Alvi SN; Binhashim N
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):78. PubMed ID: 29216899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.